ARCHIVES

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

This article is from The Cancer Letter archive.

Vol. 36 No. 24 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

President’s Budget Versus NCI’s Bypass: A Comparison

February 21, 1992

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

April 9, 2010

NCAB Okays Effort To Relax $5 Million Limit On Center Core Grants In Cancer Act Renewal

November 19, 1976

NCCS Networker Volume 10 Issue 2, Summer/Fall 1996 Special Commemorative Issue

August 13, 1996

NCI Cooperative Group, Cancer Center Trials Listed

October 28, 2005

NIH Reauthorization Compromise Between House and Senate Gives NCI Three Year Authorization Period

October 18, 1985